Table 3 Patient clinical characteristics... | American Society of Hematology

Table 3

Patient clinical characteristics

Patient no.	Age, y/sex	FAB	WBC × 10⁶/L	Blast, %	Source	FLT3	Karyotype	Previous treatment	IC₅₀, μM
1	82/M	M4	17,600	51	PB	—	Normal	No	1
2	61/M	M1	200,000	99	PB	ITD	Normal	No	0.5
3	55/F	M1	188,400	99	PB	ITD	Normal	No	0.1

Patient no.	Age, y/sex	FAB	WBC × 10⁶/L	Blast, %	Source	FLT3	Karyotype	Previous treatment	IC₅₀, μM
1	82/M	M4	17,600	51	PB	—	Normal	No	1
2	61/M	M1	200,000	99	PB	ITD	Normal	No	0.5
3	55/F	M1	188,400	99	PB	ITD	Normal	No	0.1

FAB indicates French-American-British (leukemia classification); PB, peripheral blood; ITD, internal tandem duplication; WBC, white blood cells; and —, not applicable.

Freshly isolated leukemia cells were cultured in the presence of various concentrations of Ki11502 (0.01-1 μM). After 2 days, the proliferation of cells was measured by ³[H]-thymidine uptake. Concentration of Ki11502 that induced 50% growth inhibition (IC₅₀) was calculated from the dose-response curves.

View Large

This Feature Is Available To Subscribers Only